[1] Discovery of WP1066, a novel Stat3/c-myc inhibitor with potent antitumor activity against human melanoma in vitro and in vivo
[2] A IWAMARU. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo[J]. Oncogene, 2006, 26 17: 2435-2444. DOI:
10.1038/sj.onc.1210031[3] ALESSANDRA FERRAJOLI. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.[J]. Cancer research, 2007, 67 23: 11291-11299. DOI:
10.1158/0008-5472.can-07-0593[4] LING-YUAN KONG. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.[J]. Clinical Cancer Research, 2008, 14 18: 5759-5768. DOI:
10.1158/1078-0432.ccr-08-0377[5] LING-YUAN KONG. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.[J]. Cancer Immunology, Immunotherapy, 2009, 58 7: 1023-1032. DOI:
10.1007/s00262-008-0618-y[6] CHAOYA MA. Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines.[J]. Journal of Clinical and Experimental Hematopathology, 2017, 57 1: 21-25. DOI:
10.3960/jslrt.17006